tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TG Therapeutics’ Earnings Call Highlights BRIUMVI Success

TG Therapeutics’ Earnings Call Highlights BRIUMVI Success

TG Therapeutics ((TGTX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest earnings call for TG Therapeutics showcased a positive sentiment, underscored by strong commercial performance and strategic advancements. The company highlighted the success of BRIUMVI and its subcutaneous version, although it acknowledged increased operating expenses and potential challenges from payer preferences for subcutaneous therapies.

Strong Commercial Performance

The U.S. net sales for BRIUMVI in Q2 reached approximately $139 million, surpassing internal expectations. This achievement marks the highest number of new patient enrollments since the product’s launch, indicating robust commercial performance.

Subcutaneous BRIUMVI Development

TG Therapeutics is making strides in developing a subcutaneous version of BRIUMVI. The company has initiated patient enrollment for a pivotal Phase III trial, with plans to file a Biologics License Application (BLA) in 2027 and a potential product launch in 2028.

Revenue Growth

The company reported total revenue of $141.1 million for Q2 2025, which represents a 91% increase compared to the same period last year and a 16% growth over Q1 2025. This substantial revenue growth highlights the company’s strong market position.

Net Income Increase

TG Therapeutics reported a GAAP net income of $28.2 million, or $0.17 per diluted share, for Q2 2025. This is a significant increase from $6.9 million, or $0.04 per diluted share, in Q2 2024, reflecting improved profitability.

Market Share Growth

BRIUMVI is capturing nearly one-third of new IV anti-CD20 therapy patient starts, demonstrating significant market penetration and a growing share in the competitive landscape.

Increased Operating Expenses

The company’s total operating expenses rose to approximately $71 million, driven by ongoing research and development investments and commercial efforts. This is up from $46.9 million in Q2 2024, reflecting the company’s commitment to growth.

Potential Payer Influence on Subcutaneous Preference

There are concerns about future payer preferences for lower-cost, at-home therapies, which may impact the demand for IV therapies. This potential shift could influence the company’s strategic direction.

Forward-Looking Guidance

TG Therapeutics provided an optimistic outlook, raising their full-year U.S. BRIUMVI net revenue guidance from $560-$570 million to $575 million. They anticipate stronger growth from Q3 to Q4 and continue to focus on making BRIUMVI the leading anti-CD20 therapy for relapsing multiple sclerosis. The company also maintains a strong capital position with approximately $279 million in cash and investments.

In summary, TG Therapeutics’ earnings call reflected a positive sentiment with strong commercial performance and strategic progress. The success of BRIUMVI and its market penetration were key highlights, although the company faces challenges with increased expenses and potential shifts in payer preferences. Overall, the outlook remains optimistic with raised revenue guidance and ongoing product development.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1